By Colin Kellaher

 

Merck & Co. on Wednesday said the U.S. Food and Drug Administration approved the expanded use of its Vaxneuvance 15-valent pneumococcal vaccine to include children and infants as young as six weeks of age.

The Kenilworth, N.J., drugmaker said the expanded indication makes Vaxneuvance the first pneumococcal conjugate vaccine approved in almost a decade to help protect pediatric populations against invasive pneumococcal disease.

Merck said a U.S. Centers for Disease Control and Prevention advisory committee is slated to meet later on Wednesday to discuss and make recommendations on the use of Vaxneuvance in children.

Merck last year received FDA approval of the vaccine for adults.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

June 22, 2022 07:12 ET (11:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Merck Charts.